Compound Summary
药名: | Honokiol |
别名: | VZ32385; 354H746; NCGC00163567-01; HMS2051C12; 11513CCO0N; {1,1'-Biphenyl]-2,4'-diol, 3,5-di-2-propenyl-; 2-(4-hydroxy-3-prop-2-enyl-phenyl)-4-prop-2-enyl-phenol; ZINC00001536; STK801954; AIDS002243; FVYXIJYOAGAUQK-UHFFFAOYSA-N; AC-486; SMP2_000040; 5,3′ C10630; AX8008971; NSC-293100; AS-15333; W-2613; 3',5-diallyl-2,4'-biphenyldiol; AC1Q7A9U; MLS000759481; TR-014635; 564-73-8; SR-01000758208-5; 3',5-Dipropenyl-(1,1'-biphenyl)-2,4'-diol; J10347; NC00114; SAM001246690; Bio-0326; MLS001423980; CHEBI:5759; 3'',5-diallylbiphenyl-2,4''-diol; REGID_for_CID_72303; O900; MolPort-002-507-432; SCHEMBL133034; InChI=1/C18H18O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h3-4,7-12,19-20H,1-2,5-6H; BC205226; AN-15767; ANW-56605; MCULE-5001549020; ACN-035410; 3,5'-Diallyl-4,2'-dihydroxybiphenyl; Honokiol, >=98% (HPLC), powder; D04DQJ; CTK5J3931; BG01559998; SR-01000758208; BRD-K98493452-001-01-6; AC1L2HTG; AB0016711; AKOS005622639; 4-allyl-2-(3-allyl-4-hydroxy-phenyl)phenol; AT-5464; 5,3''''-Diallyl-biphenyl-2,4''''-diol; RTR-014635; cid_72303; 2-(4-hydroxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol; 3',5-diallyl-[1,1'-biphenyl]-2,4'-diol; CHEMBL16901; 3',5-Diallyl-2,4'-dihydroxybiphenyl; 35354-74-6; 5,3′-Diallyl-2,4′-dihydroxybiphenyl; houpa; UNII-11513CCO0N; 3',5-di(prop-2-en-1-yl)biphenyl-2,4'-diol; CPD000387107; HY-N0003; HMS3393C12; Honokiol; Q-100425; FT-0601638; 5,3''-Diallyl-biphenyl-2,4''-diol; 3'',5-di-2-propenyl-1,1''-biphenyl-2,4''-diol; BBL027819; MFCD00016674; CCG-100864; ST24044036; AK-25837; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propen-1-yl-; Honokiol, analytical standard; AJ-08043; BDBM50157304; 3',1'-biphenyl)-2,4'-diol; 5,3'-Diallyl-biphenyl-2,4'-diol; NSC293100; NCGC00163567-03; BG00615873; 4CN-0876; NSC 293100; H4914_SIGMA; KS-00000NQF; 3',5'-Diallyl-2,4'-biphenyldiol; SC-17371; BN0719; NCGC00163567-02; LS-174528; BB_NC-1461; s2310; 5,3'-Diallyl-2,4'-dihydroxybiphenyl; API0002927; CS-1696; I06-0428; N1672; HMS2271J07; DTXSID30188845; SMR000387107; MLS001048916; AIDS-002243; HMS3656G03; Honokiol, HO; Honokiol, European Pharmacopoeia (EP) Reference Standard; ZINC1536; Honokiol,(S); MLS006011755; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propenyl-; 5,3′-Diallyl-2,4′-dihydroxydiphenyl; 4-allyl-2-(3-allyl-4-hydroxyphenyl)phenol; 3',5-Diallylbiphenyl-2,4'-diol |
成分: | HBIN029531 |
OB_score: | 60.669442 |
CAS_id: | 35354-74-6 |
SymMap_id: | SMIT00240 |
TCMID_id: | 9630 |
TCMSP_id: | MOL005955 |
PubChem_id: | 72303 |
植物ID | 拉丁名 | 药用植物名 | 药名 | 来源 | 功能与主治 | 使用民族 |
---|
TCMBANKHE003858 | Semen Strychni Praeparata | 炙马钱子 | Treatment of protracted arthritis, rheumatoid arthralgia, numbness and paralysis, sequala of poliomyelitis, traumatic injury, boils and sores./Treatment of protracted arthritis, rheumatoid arthralgia, numbness and paralysis, sequala of poliomyelitis, traumatic injury, boils and sores. | |||
TCMBANKHE004771 | Magnolia obovata | 日本厚朴 | ||||
TCMBANKHE005435 | Magnolia biloba | 凹叶厚朴 | See Magnolia officinalis ./See Magnolia officinalis. | |||
TCMBANKHE007292 | 藁本 | Headache due to externally contracted wind-cold, vertex headache, pain in tooth and cheek, migraine, wind-cold-damp impediment, pain in limbs. | ||||
TCMBANKHE002734/YEM-235 | Magnolia officinalis Rehd.et Wils. | 厚朴子|厚朴 | 厚朴 | 云南民族药物志:第二卷 | 彝族 | |
TCMBANKHE002025/YEM-235 | Magnoliae Officinalis Praeparata|Magnolia officinalis Rehd.et Wils. | 炙厚朴|厚朴 | 厚朴 | 云南民族药物志:第二卷 | Treatment of accumulation of damp in the spleen and the stomach marked by epigastric strffiness, vomiting and diarrhea, abdominal distension and constipation due to retention of undigested food, cough and dyspnea caused by retanied damp./1. Broad-spectrum antibacterial.2. Magnocurarine, one of the active components, can relaxstriated muscles.3. Its decoction stimulates the smooth muscles of intestines and bronchii in rabbits in vitro.4. Magnocuraine may also lower blood pressure and accelerate heart rate. | 彝族 |
TCMBANKHE005228/YEM-235 | Cortex Magnoliae officilis;Magnolia officinalis|Magnolia officinalis Rehd.et Wils. | 厚朴 | 厚朴 | 云南民族药物志:第二卷 | To eliminate damp and relieve distension;To dry damp and disperse phlegm, precipitate qi and eliminate fullness, lower blood pressure./1. Broad-spectrum antibacterial.2. Magnocurarine, one of the active components, can relaxstriated muscles.3. Its decoction stimulates the smooth muscles of intestines and bronchii in rabbits in vitro.4. Magnocuraine may also lower blood pressure and accelerate heart rate.5.Amebic dysentery, vomiting and diarrhea, food accumulation and qi stagnation, abdominal distention and constipation, phlegm-rheum cough asthma. | 彝族 |
TCMBANKHE007340/YEM-235 | Flos Magnoliae Offcinalis|Magnolia officinalis Rehd.et Wils. | 厚朴花|厚朴 | 厚朴 | 云南民族药物志:第二卷 | Treatment of feeling of stuffiness and distension in the chest and epigastrium with loss of appetite./Treatment of feeling of stuffiness and distension in the chest and epigastrium with loss of appetite. | 彝族 |
TCMBANKHE005553/YEM-839/XU-751 | Fructus Anisi Stellati|Illicium verum Hook.f.|Illicium verum | 八角茴香|八角 | 八角 | 云南民族药物志:第五卷|广西崇左大新县下雷镇德天瀑布 | To dispel cold to regulate the flow of qi and to relieve pain./Treatment of abdominal colic, lumbago due to deficiency of the kidney, vomiting and eqigastric pain due to cold of the stomach. | 阿昌族/傣族/德昂族/景颇族/傈僳族/彝族/壮族 |
疾病ID | 病名 | 疾病类型 | MeSH | 参考文献 |
---|
TCMBANKDI000001 | Stomach Neoplasms | group | Digestive System Diseases; Neoplasms | 25619450 |
TCMBANKDI000007 | melanoma | disease | Neoplasms | 30391358 |
TCMBANKDI000008 | Brain Neoplasms | group | Neoplasms; Nervous System Diseases | 22259050 |
TCMBANKDI000009 | Glioma | disease | Neoplasms | 30587839 |
TCMBANKDI000048 | Neoplasms | group | Neoplasms | 23807168 |
TCMBANKDI000051 | Endotoxemia | phenotype | Pathological Conditions, Signs and Symptoms; Infections | 21279327 |
TCMBANKDI000067 | Head and Neck Neoplasms | group | Neoplasms | 29180609 |
TCMBANKDI000070 | Osteosarcoma | disease | Neoplasms | 29410403 |
TCMBANKDI000078 | Skin Neoplasms | group | Neoplasms; Skin and Connective Tissue Diseases | 30391358 |
TCMBANKDI000085 | Inflammation | phenotype | Pathological Conditions, Signs and Symptoms | 22429472 |
TCMBANKDI000093 | Sepsis | disease | Pathological Conditions, Signs and Symptoms; Infections | 21279327 |
TCMBANKDI002310 | Kidney Neoplasm | disease | Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | 23752066 |
TCMBANKDI003011 | Staphylococcal Infections | group | Infections | 31119985 |
TCMBANKDI010465 | Sleep Initiation and Maintenance Disorders | disease | Nervous System Diseases; Mental Disorders | 22537192 |
TCMBANKDI012424 | Neoplasm Invasiveness | phenotype | Pathological Conditions, Signs and Symptoms; Neoplasms | 25619450 |
TCMBANKDI013888 | Fibrosis | phenotype | Pathological Conditions, Signs and Symptoms | 21265825 |
TCMBANKDI014031 | Peritoneal Neoplasms | group | Digestive System Diseases; Neoplasms | 30391358 |
TCMBANKDI015452 | Thyroid Neoplasm | disease | Neoplasms; Endocrine System Diseases | 27940017 |
TCMBANKDI017642 | Squamous cell carcinoma | disease | Neoplasms | 29180609 |
TCMBANKDI018012 | Ureteral obstruction | phenotype | Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | 21265825 |
TCMBANKDI018458 | Intervertebral Disc Degeneration | disease | Musculoskeletal Diseases | 29649568 |
TCMBANKDI020247 | Cardiomegaly | phenotype | Pathological Conditions, Signs and Symptoms; Cardiovascular Diseases | 25871545 |
TCMBANKDI024649 | Neuroblastoma | disease | Neoplasms | 26454217 |
TCMBANKDI026275 | Glioblastoma | disease | Neoplasms | 30587839 |
TCMBANKDI026766 | Vitiligo | disease | Skin and Connective Tissue Diseases | 31037127 |
TCMBANKDI029884 | Acute Lung Injury | disease | Respiratory Tract Diseases | 21279327 |
靶点ID | 基因名 | 基因别名 | 描述 |
---|
TCMBANKGE000118 | CAPN2 | CANP2; CANPL2; CANPml; mCANP | calpain 2 |
TCMBANKGE000139 | POR | CPR; CYPOR; P450R | cytochrome p450 oxidoreductase |
TCMBANKGE000146 | CAPN10 | CANP10; NIDDM1 | calpain 10 |
TCMBANKGE000181 | PIM1 | PIM | Pim-1 proto-oncogene, serine/threonine kinase |
TCMBANKGE000201 | ESR1 | ER; ESR; ESRA; ESTRR; Era; NR3A1 | estrogen receptor 1 |
TCMBANKGE000205 | NOS2 | HEP-NOS; INOS; NOS; NOS2A | nitric oxide synthase 2 |
TCMBANKGE000241 | CASP8 | ALPS2B; CAP4; Casp-8; FLICE; MACH; MCH5 | caspase 8 |
TCMBANKGE000276 | NOS1 | IHPS1; N-NOS; NC-NOS; NOS; bNOS; nNOS | nitric oxide synthase 1 |
TCMBANKGE000286 | GSK3B | - | glycogen synthase kinase 3 beta |
TCMBANKGE000315 | IL4 | BCGF-1; BCGF1; BSF-1; BSF1; IL-4 | interleukin 4 |
TCMBANKGE000360 | CCNA2 | CCN1; CCNA | cyclin A2 |
TCMBANKGE000458 | CYP2B6 | CPB6; CYP2B; CYP2B7; CYP2B7P; CYPIIB6; EFVM; IIB1; P450 | cytochrome P450 family 2 subfamily B member 6 |
TCMBANKGE000474 | NCOA1 | F-SRC-1; KAT13A; RIP160; SRC1; bHLHe42; bHLHe74 | nuclear receptor coactivator 1 |
TCMBANKGE000476 | NCOA2 | GRIP1; KAT13C; NCoA-2; SRC2; TIF2; bHLHe75 | nuclear receptor coactivator 2 |
TCMBANKGE000478 | CHEK1 | CHK1 | checkpoint kinase 1 |
TCMBANKGE000633 | ADRB2 | ADRB2R; ADRBR; B2AR; BAR; BETA2AR | adrenoceptor beta 2 |
TCMBANKGE000654 | CAPN1 | CANP; CANP1; CANPL1; SPG76; muCANP; muCL | calpain 1 |
TCMBANKGE000701 | ESR2 | ER-BETA; ESR-BETA; ESRB; ESTRB; Erb; NR3A2; ODG8 | estrogen receptor 2 |
TCMBANKGE000813 | DPP4 | ADABP; ADCP2; CD26; DPPIV; TP103 | dipeptidyl peptidase 4 |
TCMBANKGE000820 | CFLAR | CASH; CASP8AP1; CLARP; Casper; FLAME; FLAME-1; FLAME1; FLIP; I-FLICE; MRIT; c-FLIP; c-FLIPL; c-FLIPR; c-FLIPS; cFLIP | CASP8 and FADD like apoptosis regulator |
TCMBANKGE000903 | PTGS1 | COX1; COX3; PCOX1; PES-1; PGG/HS; PGHS-1; PGHS1; PHS1; PTGHS | prostaglandin-endoperoxide synthase 1 |
TCMBANKGE000938 | CDK2 | CDKN2; p33(CDK2) | cyclin dependent kinase 2 |
TCMBANKGE001001 | SNCA | NACP; PARK1; PARK4; PD1 | synuclein alpha |
TCMBANKGE001041 | ALOX15 | 12-LOX; 15-LOX; 15-LOX-1; LOG15 | arachidonate 15-lipoxygenase |
TCMBANKGE001045 | CCND1 | BCL1; D11S287E; PRAD1; U21B31 | cyclin D1 |
TCMBANKGE001054 | ABCA1 | ABC-1; ABC1; CERP; HDLCQTL13; HDLDT1; HPALP1; TGD | ATP binding cassette subfamily A member 1 |
TCMBANKGE001073 | PTGS2 | COX-2; COX2; GRIPGHS; PGG/HS; PGHS-2; PHS-2; hCox-2 | prostaglandin-endoperoxide synthase 2 |
TCMBANKGE001107 | NOS3 | ECNOS; eNOS | nitric oxide synthase 3 |
TCMBANKGE001131 | CASP9 | APAF-3; APAF3; ICE-LAP6; MCH6; PPP1R56 | caspase 9 |
TCMBANKGE001132 | BAX | BCL2L4 | BCL2 associated X, apoptosis regulator |
TCMBANKGE001148 | VEGFA | MVCD1; VEGF; VPF | vascular endothelial growth factor A |
TCMBANKGE001156 | CASP3 | CPP32; CPP32B; SCA-1 | caspase 3 |
TCMBANKGE001173 | MCL1 | BCL2L3; EAT; MCL1-ES; MCL1L; MCL1S; Mcl-1; TM; bcl2-L-3; mcl1/EAT | MCL1 apoptosis regulator, BCL2 family member |
TCMBANKGE001185 | PPARG | CIMT1; GLM1; NR1C3; PPARG1; PPARG2; PPARG5; PPARgamma | peroxisome proliferator activated receptor gamma |
TCMBANKGE001202 | MAPK14 | CSBP; CSBP1; CSBP2; CSPB1; EXIP; Mxi2; PRKM14; PRKM15; RK; SAPK2A; p38; p38ALPHA | mitogen-activated protein kinase 14 |
TCMBANKGE001467 | LTA4H | - | leukotriene A4 hydrolase |
TCMBANKGE001755 | MAOB | - | monoamine oxidase B |
TCMBANKGE001943 | ADRA1D | ADRA1; ADRA1A; ADRA1R; ALPHA1; DAR; dJ779E11.2 | adrenoceptor alpha 1D |
TCMBANKGE001966 | RASGRF2 | GRF2; RAS-GRF2 | Ras protein specific guanine nucleotide releasing factor 2 |
TCMBANKGE002094 | CAPN3 | CANP3; CANPL3; LGMD2; LGMD2A; LGMDD4; LGMDR1; nCL-1; p94 | calpain 3 |
TCMBANKGE003010 | CAPN9 | GC36; nCL-4 | calpain 9 |
TCMBANKGE003183 | CAPN11 | calpain11 | calpain 11 |
TCMBANKGE003625 | SLC6A4 | 5-HTT; 5-HTTLPR; 5HTT; HTT; OCD1; SERT; SERT1; hSERT | solute carrier family 6 member 4 |
TCMBANKGE004266 | AR | AIS; AR8; DHTR; HUMARA; HYSP1; KD; NR3C4; SBMA; SMAX1; TFM | androgen receptor |
TCMBANKGE005535 | CHRM1 | HM1; M1; M1R | cholinergic receptor muscarinic 1 |
TCMBANKGE006282 | CAPN8 | nCL-2 | calpain 8 |
TCMBANKGE006373 | TYW1 | RSAFD1; TYW1A; YPL207W | tRNA-yW synthesizing protein 1 homolog |
TCMBANKGE006943 | CHRM3 | EGBRS; HM3; PBS | cholinergic receptor muscarinic 3 |
TCMBANKGE007670 | CAPN12 | - | calpain 12 |
TCMBANKGE007737 | CAPN13 | - | calpain 13 |
TCMBANKGE007924 | PKIA | PRKACN1 | cAMP-dependent protein kinase inhibitor alpha |
TCMBANKGE008423 | CAPN15 | SOLH | calpain 15 |
TCMBANKGE008750 | CAPN7 | CALPAIN7; PALBH | calpain 7 |
TCMBANKGE008921 | RXRA | NR2B1 | retinoid X receptor alpha |
TCMBANKGE008975 | CAPN14 | - | calpain 14 |
TCMBANKGE009256 | SLC6A2 | NAT1; NET; NET1; SLC6A5 | solute carrier family 6 member 2 |
TCMBANKGE009776 | CAPN6 | CANPX; CAPNX; CalpM; DJ914P14.1 | calpain 6 |
TCMBANKGE009863 | MTRR | MSR; cblE | 5-methyltetrahydrofolate-homocysteine methyltransferase reductase |
TCMBANKGE010043 | PPIF | CYP3; CyP-M; Cyp-D; CypD | peptidylprolyl isomerase F |
TCMBANKGE011079 | PRSS1 | TRP1; TRY1; TRY4; TRYP1 | serine protease 1 |
TCMBANKGE011356 | NDOR1 | CIAE1; NR1; bA350O14.9 | NADPH dependent diflavin oxidoreductase 1 |
TCMBANKGE011544 | IGHG1 | - | immunoglobulin heavy constant gamma 1 (G1m marker) |
TCMBANKGE011625 | ADGB | C6orf103; CAPN16 | androglobin |
TCMBANKGE011923 | CHRM4 | HM4; M4R | cholinergic receptor muscarinic 4 |
TCMBANKGE012155 | SLC6A3 | DAT; DAT1; PKDYS; PKDYS1 | solute carrier family 6 member 3 |
TCMBANKGE014062 | CAPN5 | ADNIV; HTRA3; VRNI; nCL-3 | calpain 5 |
TCMBANKGE014423 | ADRA1A | ADRA1C; ADRA1L1; ALPHA1AAR | adrenoceptor alpha 1A |